R&D | May 25, 2026
AstraZeneca to showcase cancer pipeline push at ASCO 2026
Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies
Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies
The decision now moves to the European Commission, with a final ruling expected by the third quarter of 2026
The company said all doses achieved statistically significant reductions in body weight compared with placebo at 72 weeks
If cleared, MAVIRET would become one of the few therapies in the European Union approved to treat both acute and chronic hepatitis C infections
The recommendation is powered by blockbuster results from the pivotal Phase III SERENA-6 trial
Expands Davaindia network to 2,579 stores
If approved, TEV-‘749 would mark a shift toward long-acting care aimed at improving treatment adherence in real-world settings
The decision marks a key step in the centralized EU review process
New regulation mandates stricter prescription monitoring, sales record maintenance, and enhanced compliance across the pharmaceutical supply chain
The new CRS offering is delivered from WACKER’s Biotechnology Center in Munich
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
